Ceftriaxone plus amikacin in a single daily dose as empiric antibiotic therapy in granulocytopenic patients.
In our study ceftriaxone plus amikacin were employed as empirical antibiotic therapy. This antibiotic treatment allows for a once daily administration and has a broad spectrum of activity. 21 febrile episodes were treated with an antibiotic regimen of ceftriaxone 50 mg/kg/day and amikacin 30-35 mg/kg/day i.v. An earlier pilot study was carried out in which 47 febrile episodes were treated with an antibiotic regimen of ceftriaxone 80-100 mg/kg/day i.v. and amikacin 30-35 mg/kg/day i.v. in a single dose. The overall response rate was 76% (16/21) and 79% (37/47) for the pilot study. During the treatment no side effects were observed and aminoglycoside related toxicity did not occur. In conclusion, this empiric antibiotic therapy gives a high response rate and allows for a single daily administration.
Cudillo
L
L
Cattedra di Ematologia, Università di Tor Vergata, Ospedale S. Eugenio, Rome, Italy.
Masi
M
M
Scimò
M T
MT
Tribalto
M
M
Cantonetti
M
M
Criscuolo
D
D
Papa
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000150:complications*; D000583:Amikacin / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000517:prevention & control*; D002443:Ceftriaxone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged
D002443:Ceftriaxone; D000583:Amikacin